Agenus Inc
AGEN
Market Cap$78.71M
Close$
$-6.07
299.7% downside
Current Fair Value
299.7% downsideOvervalued by 299.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $78.71 Million |
|---|---|
| Enterprise Value | $133.17 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-10.59 |
| Beta | 1.58 |
| Outstanding Shares | 22,506,372 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.31 |
|---|---|
| PEG | 33.09 |
| Price to Sales | 0.76 |
| Price to Book Ratio | -0.22 |
| Enterprise Value to Revenue | 1.29 |
| Enterprise Value to EBIT | -1.49 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.71 |
| Debt to Equity | -0.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...